Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 153Sarcoma 3Genitourinary 3Breast 3Thoracic 2Dermatologic 2Gastrointestinal 1

Conditions

Melanoma 42Carcinoma, Non-Small-Cell Lung 13Carcinoma, Renal Cell 10Colorectal Neoplasms 9Neoplasm Metastasis 8Ovarian Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Pancreatic Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Ovarian Epithelial 4Uveal Melanoma 3Esophageal Neoplasms 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Sezary Syndrome 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Melanoma, Cutaneous Malignant 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2

Interventions

pembrolizumab 6Paclitaxel 2Nivolumab 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2Cyclophosphamide 2Carboplatin 2veliparib 1selinexor 1olaparib 1liposomal doxorubicin 1eribulin 1entinostat 1dehydroftorafur 1Topotecan 1Temozolomide 1Taxes 1Specimen Handling 1Ramucirumab 1Quality of Life 1Polymerase Chain Reaction 1Pemetrexed 1Patient Reported Outcome Measures 1Paracentesis 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Microarray Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Paclitaxel × Dermatologic × Clear all
NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡